The Human Trisome Project
Part of paid clinical trials in Denver, Colorado.
- Sponsor
- University of Colorado, Denver
- Study ID
- NCT02864108
- Status
- Recruiting
Conditions
- Down Syndrome
- Trisomy 21
Eligibility Criteria
- Sex
- ALL
- Age
- 6 Months - 89 Years
- Healthy Volunteers
- Accepted
Study Details
The Human Trisome Project will significantly increase the speed of Down syndrome research and the understanding of associated medical conditions. Its biobank will provide de-identified samples to research.
Key Dates
- Start date
- Jul 31, 2016
- Status verified
- Oct 2025
- Primary completion
- Jul 31, 2036
- Completion
- Jul 31, 2036
Study Design
- Enrollment
- 2,500 participants (estimated)
Arms
- Arm: Those with trisomy 21People aged 6 months to 89 years old who have some form of trisomy 21.
- Arm: ControlsPeople aged 6 months to 89 years old who do not have trisomy 21. These persons can be related to someone with some form of trisomy 21 but do not have to be related.
Primary Outcome Measure
Number of Participants and Controls Enrolled in Biobank [ Time Frame: 5 years ]
Central Contacts
- Angela Rachubinski, PhD(303) 724-7366
- Constance Brecl, BA
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Linda Crnic Institute for Down Syndrome at the University of Colorado Denver | Denver | Colorado | 80045 | Joaquin Espinosa, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Denver, CO
Related Studies
- DS-Connect®: The Down Syndrome RegistryRecruiting · University of Colorado, Denver · Aurora, Colorado
- Trial-Ready Cohort-Down Syndrome (TRC-DS)Recruiting · University of Southern California · Phoenix, Arizona
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Recruiting · Duke University · Phoenix, Arizona
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)PHASE2 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama